Neurocrine Biosciences Inc
(NAS:NBIX)
$
126.59
-1.32 (-1.03%)
Market Cap: 12.82 Bil
Enterprise Value: 11.84 Bil
PE Ratio: 33.94
PB Ratio: 4.71
GF Score: 85/100 Neurocrine Biosciences Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 14, 2020 / 05:30PM GMT
Release Date Price:
$106.03
(+5.62%)
Jeff Hung
Morgan Stanley, Research Division - Equity Analyst
Welcome to Global Healthcare Conference. I'm Jeff Hung, one of the Biotech analysts. (Operator Instruction] For important disclosures, please see the Morgan Stanley Research Disclosure website at www.morganstanley.com/researchdisclosures. (Operator Instructions) So for this session, we have from Neurocrine Biosciences, CEO, Kevin Gorman; and CFO, Matt Abernethy. Welcome, guys.
Kevin C. Gorman
Neurocrine Biosciences, Inc. - CEO & Director
Welcome, Jeff, and thank you very much for the opportunity to speak here today.
Jeff Hung
Morgan Stanley, Research Division - Equity Analyst
Yes. So for those who may not be familiar with Neurocrine, can you provide a brief introduction?
Kevin C. Gorman
Neurocrine Biosciences, Inc. - CEO & Director
Certainly. And before I start, Matt and I will be making forward-looking
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot